3 results
Approved WMOWill not start
Primary: Safety and tolerability of 2 dosages of ambrisentan. Secundary: Efficacy and PK.
Approved WMOWill not start
Primary: Longterm safety and tolerability of 2 dosages of ambrisentan. Secundary: Supportive efficacy data.
Approved WMOCompleted
The aim of the study is to assess the risk of impaired driving in the morning at 3 and 4 hours after a middle-of-the-night dose of zolpidem tartrate sublingual tablet 3.5 mg.